Lu, C., Huang, C., Wu, I., Tsai, H., Ma, C., Yeh, Y., . . . Wang, J. (2015). Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()(). Transl Oncol.
Chicago Stili AlıntıLu, Chien-Yu, Ching-Wen Huang, I-Chen Wu, Hsiang-Lin Tsai, Cheng-Jen Ma, Yung-Sung Yeh, Se-Fen Chang, Meng-Lin Huang, ve Jaw-Yuan Wang. "Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI in the First-line Setting()()." Transl Oncol 2015.
MLA AlıntıLu, Chien-Yu, et al. "Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI in the First-line Setting()()." Transl Oncol 2015.